KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) EBITDA (2016 - 2026)

Esperion Therapeutics filings provide 8 years of EBITDA readings, the most recent being $61.8 million for Q4 2025.

  • On a quarterly basis, EBITDA rose 390.04% to $61.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$22.7 million, a 56.17% increase, with the full-year FY2025 number at -$22.7 million, up 56.17% from a year prior.
  • EBITDA hit $61.8 million in Q4 2025 for Esperion Therapeutics, up from -$31.3 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $61.8 million in Q4 2025 to a low of -$90.9 million in Q1 2021.
  • Median EBITDA over the past 5 years was -$52.4 million (2022), compared with a mean of -$39.3 million.
  • The widest YoY moves for EBITDA: up 390.04% in 2025, down 166.3% in 2025.
  • Esperion Therapeutics' EBITDA stood at -$65.1 million in 2021, then rose by 14.97% to -$55.4 million in 2022, then decreased by 1.71% to -$56.3 million in 2023, then skyrocketed by 62.16% to -$21.3 million in 2024, then skyrocketed by 390.04% to $61.8 million in 2025.
  • The last three reported values for EBITDA were $61.8 million (Q4 2025), -$31.3 million (Q3 2025), and -$12.7 million (Q2 2025) per Business Quant data.